<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%5BNLMID%5D&amp;v=2.18.0.post =期刊＆ff = 20250213111310<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_content=101560960&amp;utm_medium=rss&amp;fc=None&amp;utm_campaign=journals&amp;ff=20250213111310" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate> THU，2025年2月13日16:13:11 +0000</lastbuilddate><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title> HCC患者的基于放射学的生物标志物用于PD-1状态和预后分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944703/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description>结论：基于放射线签名的拟议模型有助于评估HCC患者的PD-1状态，并可用于评估最有可能受益于索拉非尼作为免疫检查点疗法的潜在组合治疗方案的患者。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1435668。 doi：10.3389/fimmu.2025.1435668。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：研究基于术前增强CT的放射素学模型对肝细胞癌（HCC）患者PD-1预测的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：该研究包括105名HCC患者（培训队列：72；验证队列：33），他们接受了术前对比度增强的CT并在手术后接受了全身性索拉非尼治疗。为每个患者建立了放射素学评分，并使用多变量逻辑回归分析与独立的临床放射学预测指标整合到放射线学模型中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：最终选择了17个放射线特征来构建放射线分数。在多元分析中，血清肌酸和周围增强是PD-1预测的重要独立因素。放射学模型与血清肌酸和周围增强的整合放射素学签名显示出良好的判别性能（在培训和验证队列中为0.897和0.794）。放射素学预测的PD-1阳性和PD-1阴性组之间的总生存期（OS）显着差异（OS：29.66个月，CI：16.03-44.40 vs. 31.04个月，CI：17.10-44.07，P &lt;0.001，P &lt;0.001 ）。放射学预测的PD-1是手术后用索拉非尼治疗的患者OS的独立预测指标。 （危险比[HR]：1.61 [1.23-2.1]，p &lt;0.001）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：基于放射线签名的拟议模型有助于评估HCC患者的PD-1状态，并可用于评估最有可能受益于索拉非尼作为免疫检查点疗法的潜在组合治疗方案的患者。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944703/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944703</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11813882/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11813882</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1435668>10.3389/fimmu.2025.1435668</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944703</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Gulizaina Hapaer</dc:creator><dc:creator>冯切</dc:creator><dc:creator>清楚</dc:creator><dc:creator>列李</dc:creator><dc:creator>Ailin Liang</dc:creator><dc:creator>周王</dc:creator><dc:creator>Jituome Ziluo</dc:creator><dc:creator> Xin Zhang</dc:creator><dc:creator>是的</dc:creator><dc:creator>元元</dc:creator><dc:creator>bin歌曲</dc:creator><dc:date>2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>HCC患者的基于放射学的生物标志物用于PD-1状态和预后分析</dc:title><dc:identifier>PMID：39944703</dc:identifier><dc:identifier> PMC：PMC11813882</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1435668</dc:identifier></item><item><title>雷纳病毒感染后，大嘴鲈（&lt;em>; micropterus salmoides &lt;/em>;）中的免疫球蛋白M反应</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944702/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description>免疫球蛋白M（IgM）和IgM^（+）B细胞是体液免疫系统的关键组成部分，可防御病原体侵袭。尽管已经部分研究了IgM在鱼类对寄生虫和细菌的全身性和粘膜免疫反应中的作用，但其在病毒感染中的功能仍未被逐渐解散。这项研究成功地开发了一种大嘴鲈鱼（Micropterus salmoides）模型，用于雷纳维病毒浸入感染。我们的发现表明，病毒感染引起了... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1515684。 doi：10.3389/fimmu.2025.1515684。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">免疫球蛋白M（IgM）和IgM <sup>+</sup> B细胞是体液免疫系统的关键组成部分，可防御病原体侵袭。尽管已经部分研究了IgM在鱼类对寄生虫和细菌的全身性和粘膜免疫反应中的作用，但其在病毒感染中的功能仍未被逐渐解散。这项研究成功地开发了一种大嘴鲈鱼（ <i>Micropterus salmoides</i> ）模型，用于雷纳维病毒浸入感染。我们的发现表明，病毒感染引起了g和头部肾脏组织的显着病理变化，以及自适应免疫基因表达的明显上调。有趣的是，在初始病毒感染中幸存下来的鱼在暴露于较高病毒浓度的情况下，在g和头肾组织中表现出最小的死亡率和低病毒载荷。值得注意的是，在这些患有继发性感染的鱼类中，血液和the粘粘液中的IgM蛋白水平显着升高，以及g和头部肾脏组织中IgM <sup>+</sup> B细胞的明显积累。此外，血清中含有高水平的病毒特异性IgM，这表明了中和病毒的能力。这些发现突出了IgM在大嘴鲈鱼对病毒感染的免疫反应中的关键作用，并提出其潜力是增强水产养殖中病毒抗性的靶标。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944702/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944702</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814181/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814181</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1515684>10.3389/fimmu.2025.1515684</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944702</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Zhenyu黄</dc:creator><dc:creator>Naicheng Liu</dc:creator><dc:creator> Mingyang Xue</dc:creator><dc:creator> Chen Xu</dc:creator><dc:creator> yuding粉丝</dc:creator><dc:creator>YAN MENG</dc:creator><dc:creator>南江</dc:creator><dc:creator>yiqun li</dc:creator><dc:creator> Wenzhi Liu</dc:creator><dc:creator>杨</dc:creator><dc:creator>杨周</dc:creator><dc:date>2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>雷纳病毒感染后，大嘴鲈（&lt;em>; micropterus salmoides &lt;/em>;）中的免疫球蛋白M反应</dc:title><dc:identifier>PMID：39944702</dc:identifier><dc:identifier> PMC：PMC11814181</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1515684</dc:identifier></item><item><title>病例报告：抗中性粒细胞胞质抗体相关的血管炎的自发肾脏出血</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944701/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description>抗中性粒细胞胞质抗体（ANCA）相关的血管炎（AAV）是一种全身性坏死性血管炎，主要影响小血管。在本报告中，我们提出了一种典型的肉芽肿病，呈肉芽肿（GPA），这是由于自发性肾脏出血（SRH）复杂的，这是一种罕见但可能严重的疾病。该患者在免疫抑制治疗期间患有SRH，但在保守治疗后恢复。然后，我们在...中对SRH进行了系统的文献综述。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1544263。 doi：10.3389/fimmu.2025.1544263。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">抗中性粒细胞胞质抗体（ANCA）相关的血管炎（AAV）是一种全身性坏死性血管炎，主要影响小血管。在本报告中，我们提出了一种典型的肉芽肿病，呈肉芽肿（GPA），这是由于自发性肾脏出血（SRH）复杂的，这是一种罕见但可能严重的疾病。该患者在免疫抑制治疗期间患有SRH，但在保守治疗后恢复。然后，我们在AAV的背景下对SRH进行了系统的文献综述，并分析了临床特征，管理策略和患者预后。共有15名患者进行了统计分析，其中包括当前研究中报道的一个病例，其中14例来自文献。在这些患者中，有9例GPA和六名患者显示了微观多血管炎（MPA），性别分布为女性3：2男性。平均患者年龄为54.5岁，范围从25至82岁不等。急性侧面疼痛是最常见的临床表现，偶尔伴有贫血和休克。不同患者的治疗各不相同。八名患者接受了糖皮质激素和免疫抑制剂，包括利妥昔单抗，环磷酰胺和硫唑嘌呤。五名患者接受了经导管动脉栓塞（TAE）；一名患者接受了肾切除术。我们的发现表明，SRH通常发生在AAV的早期，并且与疾病活动相关，肾动脉瘤破裂是主要原因。超过一半的患者对皮质类固醇和免疫抑制剂的反应很好。及时的TAE对于尽管有保守的管理，对表现出持续恶化的患者至关重要。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944701/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944701</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11813874/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11813874</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1544263>10.3389/fimmu.2025.1544263</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944701</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Ruohan Yu</dc:creator><dc:creator>莉娜张</dc:creator><dc:creator>ting很长</dc:creator><dc:creator>hui gao</dc:creator><dc:creator> Jing Xu</dc:creator><dc:creator> Tong Zhang</dc:creator><dc:creator> Shengguang li</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>病例报告：抗中性粒细胞胞质抗体相关的血管炎的自发肾脏出血</dc:title><dc:identifier>PMID：39944701</dc:identifier><dc:identifier> PMC：PMC11813874</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1544263</dc:identifier></item><item><title>外周血免疫炎性生物标志物：术后长期生存和慢性术后乳腺癌的前瞻性预测指标</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944700/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = journals&amp;utm_contm_content = 101560960＆fc = none＆fc = nOone&amp;ff=20250210210210210211111111111111111111111111111111111111111111111111111111311111111111111111111111111111111111111111111111111111111111111111219太1119来就<description>结论：术前SIRI升高是手术后乳腺癌患者DFS差的独立危险因素。相反，围手术期免疫炎性生物标志物预测接受乳腺癌手术的患者CPSP的潜力有限。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1531639。 doi：10.3389/fimmu.2025.1531639。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：乳腺癌患者的肿瘤进展和慢性术后疼痛（CPSP）都受炎症的显着影响。免疫炎症生物标志物与长期生存以及CPSP之间的关联仍然模棱两可。这项研究检查了免疫炎性生物标志物对长期生存和CPSP的预测价值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：关于80例接受乳腺癌手术的患者的临床病理特征和围手术期外周血免疫炎性生物标志物的数据。术前免疫炎性生物标志物的最佳临界值，包括术前全身免疫感染指数（SII），全身性炎症反应指数（SIRI），中性粒细胞与lymphocyphocyte的比率（NLR）和PAN-mune-Mune-Mune-inflammation Alumation（PIV）（PIV）通过接收器操作特征（ROC）曲线建立。 Kaplan-Meier曲线和Cox回归分析用于评估术前免疫炎性生物标志物与长期生存之间的关系。进一步评估围手术期嗜中性粒细胞计数（NEU），单核细胞计数（Mono），淋巴细胞计数（LYM），血小板计数（PLT），SII，SIRI，NLR，NLR，PIV，周围血细胞计数和CPSP的动态变化使用逻辑回归分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：Kaplan-Meier曲线显示，术前SII，SIRI，NLR和PIV组的无疾病生存率（DFS）和总生存期（OS）相当长。多元COX回归分析表明，术前SIRI升高是术后DFS的独立危险因素（HR = 8.890，P = 0.038）。 CPSP的发病率为28.75％。单变量逻辑回归分析表明，体重指数（BMI），术后NEU，MONO，SIRI和PIV与CPSP的发生负相关，而随后的多元逻辑回归分析表明，只有BMI与CPSP独立相关（OR = 0.2622（OR = 0.2622）） ，p = 0.023）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：术前SIRI升高是手术后乳腺癌患者DFS差的独立危险因素。相反，围手术期免疫炎性生物标志物预测接受乳腺癌手术的患者CPSP的潜力有限。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944700/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944700</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11813937/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11813937</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1531639>10.3389/fimmu.2025.1531639</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944700</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> baoli li</dc:creator><dc:creator>李切</dc:creator><dc:creator>Huixian Li</dc:creator><dc:creator> Fangdi Min</dc:creator><dc:creator> BOLUN AI</dc:creator><dc:creator> Linxin Wu</dc:creator><dc:creator>太极拳</dc:creator><dc:creator>Peixin tan</dc:creator><dc:creator> bingbing fu</dc:creator><dc:creator> jiashuo Yang</dc:creator><dc:creator> yi fang</dc:creator><dc:creator> Hui Zheng</dc:creator><dc:creator>陶</dc:creator><dc:date>2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>外周血免疫炎性生物标志物：术后长期生存和慢性术后乳腺癌的前瞻性预测指标</dc:title><dc:identifier>PMID：39944700</dc:identifier><dc:identifier> PMC：PMC11813937</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1531639</dc:identifier></item><item><title>社论：癌症免疫和免疫疗法中腺苷途径的社区系列，第二卷</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944698/？<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1538930。 doi：10.3389/fimmu.2025.1538930。环保2025。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944698/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944698</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814425/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814425</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1538930>10.3389/fimmu.2025.1538930</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944698</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Junjiang Fu</dc:creator><dc:creator>卢卡·安东尼奥利（Luca Antonioli）</dc:creator><dc:creator>小郑</dc:creator><dc:creator>Ali H El-Far</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>社论：癌症免疫和免疫疗法中腺苷途径的社区系列，第二卷</dc:title><dc:identifier>PMID：39944698</dc:identifier><dc:identifier> PMC：PMC11814425</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1538930</dc:identifier></item><item><title>涉及动脉粥样硬化的免疫力的细胞方面</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description>动脉粥样硬化，以前被认为是一种脂质储存疾病，现已被归类为慢性炎症性疾病。动脉血管的硬化是由于脂质在动脉壁中积累而导致的动脉粥样硬化，从而引起炎症反应。动脉粥样硬化的发展发生在各个阶段，并由许多临床因素（例如高血压，高脂血症和炎症状态）促进。大量细胞已与其... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1461535。 doi：10.3389/fimmu.2025.1461535。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">动脉粥样硬化，以前被认为是一种脂质储存疾病，现已被归类为慢性炎症性疾病。动脉血管的硬化是由于脂质在动脉壁中积累而导致的动脉粥样硬化，从而引起炎症反应。动脉粥样硬化的发展发生在各个阶段，并由许多临床因素（例如高血压，高脂血症和炎症状态）促进。大量细胞已经与其发育有关。这篇综述将总结动脉粥样硬化形成的阶段以及促进或抑制其发育的所有细胞。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944697/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944697</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11813763/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11813763</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1461535>10.3389/fimmu.2025.1461535</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944697</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator>哈利尔·哈拉夫（Khalil Khalaf）</dc:creator><dc:creator>马克·夏伊（Marc Chamieh）</dc:creator><dc:creator>纳塔利亚·韦尔克（Natalia welc）</dc:creator><dc:creator> Chandpreet Singh</dc:creator><dc:creator>乔安妮·林恩·考克（Joanne Lynn Kaouk）</dc:creator><dc:creator>艾登·考克（Aiden Kaouk）</dc:creator><dc:creator> Andrzej Mackiewicz</dc:creator><dc:creator> Mariusz Kaczmarek</dc:creator><dc:creator> Bartlomiej Perek</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>涉及动脉粥样硬化的免疫力的细胞方面</dc:title><dc:identifier>PMID：39944697</dc:identifier><dc:identifier> PMC：PMC11813763</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1461535</dc:identifier></item><item><title>啮齿动物全眼移植中的免疫反应：阐明和对拒绝诊断和监测的初步研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description>结论：这项研究提供了对潮湿，揭开快速和复杂拒绝机制的免疫反应的首次全面探索。早期生物标志物的鉴定和非侵入性监测技术的发展显着提高了我们对湿排斥的理解。此外，这些发现为在这个不断发展的领域中的未来研究树立了必不可少的基准。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1475055。 doi：10.3389/fimmu.2025.1475055。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：全眼移植（湿）为视力恢复提供了潜力，但受到免疫排斥的复杂挑战的阻碍。理解和密切监测这些免疫反应对于推进湿而至关重要。这项研究深入研究了在没有免疫抑制的啮齿动物模型中免疫反应的时间表和性质，旨在阐明移植后免疫景观的详细情况，并建立创新的诊断和监测方法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们采用了一种多面方法来分析润湿后的免疫反应，包括评估角膜透明度，厚度和皮肤状况的总变化。眼皮组织和周围皮肤组织的组织病理学检查提供了对细胞变化的见解，并由眼部RT-QPCR进行了补充，用于分子分析。血清学分析用于量化细胞因子，趋化因子和供体特异性抗体，旨在鉴定与湿排斥相关的潜在生物标志物，并验证抗体介导的排斥反应的存在。这些方法共同有助于开发湿的非侵入性诊断和监测策略。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们的研究揭示了潮湿后的快速和急性免疫反应，其特征是早期的先天免疫反应以补体的参与为主，以及术后日（POD）2的中性粒细胞和单核细胞浸润。细胞介导的免疫反应主要涉及T辅助1（Th1）细胞和细胞毒性T淋巴细胞（CTL）。观察到了排斥早期阶段的供体特异性抗体（DSA）的存在和凋亡的适应症。值得注意的是，POD4的血清CXCL10的早期升高，再加上眼CD3+细胞浸润，成为潜在的早期生物标志物，用于湿排斥。此外，角膜透明度分级被证明是一种非侵入性监测工具。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究提供了对潮湿，揭开快速和复杂拒绝机制的免疫反应的首次全面探索。早期生物标志物的鉴定和非侵入性监测技术的发展显着提高了我们对湿排斥的理解。此外，这些发现为在这个不断发展的领域中的未来研究树立了必不可少的基准。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944695/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944695</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814173/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814173</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1475055>10.3389/fimmu.2025.1475055</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944695</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> bing li</dc:creator><dc:creator>王王</dc:creator><dc:creator>查尔斯·欧文斯（Charles R Owens）</dc:creator><dc:creator> Touka Banaee</dc:creator><dc:creator> Charleen T Chu</dc:creator><dc:creator> Kayvon Jabbari</dc:creator><dc:creator>安娜·李（Anna D Lee）</dc:creator><dc:creator>尼尔·J·哈特（Neil J Khatter）</dc:creator><dc:creator>艾伦·格拉斯坦</dc:creator><dc:creator>an-jey a su</dc:creator><dc:creator>克里斯蒂娜·恩</dc:creator><dc:creator>起亚M华盛顿</dc:creator><dc:date>2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>啮齿动物全眼移植中的免疫反应：阐明和对拒绝诊断和监测的初步研究</dc:title><dc:identifier>PMID：39944695</dc:identifier><dc:identifier> PMC：PMC11814173</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1475055</dc:identifier></item><item><title>高盐饮食在抗癌进展中的作用的最新进展</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944693/？<description>饮食行为显着影响肿瘤的进展，近年来对高盐饮食（HSD）的关注越来越多。传统上，HSD被认为是多个健康问题的主要危险因素，包括高血压，心血管疾病，肾脏疾病，癌症和骨质疏松症。但是，最近的研究发现了HSD的新方面，表明HSD通过调节免疫细胞的活性来抑制特定病理条件下的肿瘤生长。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1542157。 doi：10.3389/fimmu.2025.1542157。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">饮食行为显着影响肿瘤的进展，近年来对高盐饮食（HSD）的关注越来越多。传统上，HSD被认为是多个健康问题的主要危险因素，包括高血压，心血管疾病，肾脏疾病，癌症和骨质疏松症。然而，最近的研究发现了HSD的新方面，表明HSD可能通过调节浸润肿瘤的免疫细胞活性并增强PD-1免疫疗法的有效性，从而抑制特定病理条件下的肿瘤生长。这篇综述的重点是基于肿瘤微环境，肠道微生物群和钠转运蛋白转运蛋白通道的参与，基于HSD在癌症发育中的对决分子机制。这篇综述的目的是探索在特定情况下HSD是否可能是未来的肿瘤治疗策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944693/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944693</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814453/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814453</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1542157>10.3389/fimmu.2025.1542157</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944693</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Shiwei Tang</dc:creator><dc:creator>胡安Xu</dc:creator><dc:creator> ping wan</dc:creator><dc:creator> Shumen Jin</dc:creator><dc:creator> Zhang</dc:creator><dc:creator> Linting Xun</dc:creator><dc:creator>金里·王</dc:creator><dc:creator>Mei Luo</dc:creator><dc:creator> Wenjie Chen</dc:creator><dc:creator> Zan Zuo</dc:creator><dc:creator> Hui Tang</dc:creator><dc:creator> Jialong Qi</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>高盐饮食在抗癌进展中的作用的最新进展</dc:title><dc:identifier>PMID：39944693</dc:identifier><dc:identifier> PMC：PMC11814453</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1542157</dc:identifier></item><item><title>供体衍生的无细胞DNA，用于检测肺移植受者急性排斥的DNA</title><link/> https://pubmed.ncbi.nlm.nih.gov/39944692/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description>简介：急性排斥是发展慢性肺同种异体功能障碍的重要危险因素。当前的监测工具，经支气管活检和HLA抗体确定，在检测急性排斥反应方面存在局限性。这项研究旨在探索供体衍生的无细胞DNA（DDCFDNA）作为一种非侵入性生物标志物检测肺移植受者（LTR）中急性排斥反应的潜在效用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1531774。 doi：10.3389/fimmu.2025.1531774。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：急性排斥是发展慢性肺同种异体功能障碍的重要危险因素。当前的监测工具，经支气管活检和HLA抗体确定，在检测急性排斥反应方面存在局限性。这项研究旨在探索供体衍生的无细胞DNA（DDCFDNA）作为一种非侵入性生物标志物检测肺移植受者（LTR）中急性排斥反应的潜在效用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们开发了一种基于数字液滴PCR的分子方法，以确定DDCFDNA的总量和比例。使用从81 LTR的同类中收集的血液样本，我们比较了急性细胞排斥（ACR），抗体介导的排斥反应（AMR），感染或肺功能下降（FEV <sub>1 1）患者的中位水平DDCFDNA（FEV 1）（FEV 1）</sub> ）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：ACR组（1.92％[0.70％，2.30％]，p = 0.0006），AMR（1.27％[0.34％，2.29％]，P = 0.0009），分离的淋巴淋巴虫炎（分离的淋巴细胞chiolicotion（分离）淋巴细胞chiolicotion（0.70％，2.30％），AMR（1.27％[0.70％，2.30％），p = 0.0006）的中值％ddcfDNA水平明显更高。 0.54％[0.23％，2.18％]，p = 0.03）和30天内的感染或延长通气（0.50％[0.22％，2.35％]，p = 0.005），稳定的同种异体移植功能组（0.26％[0.09％，[0.09％，，， 0.60％]）。与12个月后稳定或改善FEV1的患者相比，FEV1损失患者的DDCFDNA水平也升高（1.98％，<i>而</i>1.36％，p = 0.04）。计算％DDCFDNA的最佳截止值为0.73％，以检测具有80％特异性和68％敏感性的ACR和AMR。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：％DDCFDNA是由于LTR急性排斥而导致同种异体移植损伤的有前途的生物标志物，并且可能是监测同种异体健康健康的宝贵工具。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944692/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944692</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814210/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814210</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1531774>10.3389/fimmu.2025.1531774</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944692</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> GökceYavuz</dc:creator><dc:creator>朱莉娅·沃尔特（Julia Walter）</dc:creator><dc:creator> Kaimo Hirv</dc:creator><dc:creator>奥利弗·沃克特（Oliver Wachter）</dc:creator><dc:creator>安德里亚·迪克（Andrea Dick）</dc:creator><dc:creator>朱莉娅·科瓦克斯（Julia Kovacs）</dc:creator><dc:creator>朱莉娅·齐默尔曼（Julia Zimmermann）</dc:creator><dc:creator> Olaf M Glueck</dc:creator><dc:creator> Maximilian Vorstandlechner</dc:creator><dc:creator>妮可·萨姆</dc:creator><dc:creator>Jan M Fordmann</dc:creator><dc:creator> Wulf Sienel</dc:creator><dc:creator>塞巴斯蒂安·米歇尔（Sebastian Michel）</dc:creator><dc:creator>迈克尔·欧尔贝克（Michael Irlbeck）</dc:creator><dc:creator> Nikolaus Kneidinger</dc:creator><dc:creator>鲁道夫·哈兹（Rudolf Hatz）</dc:creator><dc:creator> JürgenBehr</dc:creator><dc:creator>克里斯蒂安·施耐德（Christian Schneider）</dc:creator><dc:creator>特雷莎·考震</dc:creator><dc:date>2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>供体衍生的无细胞DNA，用于检测肺移植受者急性排斥的DNA</dc:title><dc:identifier> PMID：39944692</dc:identifier><dc:identifier> PMC：PMC11814210</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1531774</dc:identifier></item><item><title>线粒体SIRTUIN SIRT5在琥珀酸修饰和癌症发展中的新兴作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944690/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description>琥珀酰化代表了新兴的翻译后修饰（PTMS），其特征在于将带负电荷的四碳琥珀酰基基团的酶促或非酶转移转移至lysine残基的ϵ氨基残基，最近由氧甲基糖酶A介导的A。研究强调了琥珀酰化参与各种疾病，尤其是癌症的进展。 Sirtuin 5（Sirt5）是Sirtuin家族的成员，已广泛研究其强大的desuccinylase ... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1531246。 doi：10.3389/fimmu.2025.1531246。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">琥珀酰化代表了新兴的翻译后修饰（PTMS），其特征在于将带负电荷的四碳琥珀酰基基团的酶促或非酶转移转移至lysine残基的ϵ氨基残基，最近由氧甲基糖酶A介导的A。研究强调了琥珀酰化参与各种疾病，尤其是癌症的进展。 Sirtuin 5（Sirt5）是Sirtuin家族的成员，已与其脱乙酰基酶功能一起广泛研究其可靠的去甲甲基酶活性。迄今为止，仅确定了有限数量的SIRT5基材。这些底物介导了多种生理过程，例如葡萄糖氧化，脂肪酸氧化，氨解毒，活性氧氧化物种清除，抗凋亡和炎症反应。这些活动的调节可以通过作用于不同底物的相同酶活性或针对相同底物的不同酶促活性进行。 SIRT5的异常表达与肿瘤发生和疾病进展密切相关。但是，它的作用仍然有争议。 SIRT5具有双重功能：它可以促进肿瘤增殖，转移，耐药性和代谢重编程，从而充当致癌基因；相反，它还可以抑制肿瘤细胞的生长并诱导凋亡，充当肿瘤抑制基因。这篇评论旨在详述SIRT5当前研究状态的全面概述。我们讨论其结构特征和调节机制，将其功能与其他Sirtuin家族成员进行比较，并阐明调节SIRT5活性的机制。具体而言，我们关注由SIRT5在肿瘤进展中介导的琥珀酰化修饰的作用，强调了SIRT5的去甲甲基化如何调节肿瘤的发展并描述所涉及的潜在机制。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944690/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944690</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814216/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814216</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1531246>10.3389/fimmu.2025.1531246</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944690</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Zhangmin Ke</dc:creator><dc:creator> Kaikai Shen</dc:creator><dc:creator>李王</dc:creator><dc:creator>hao Xu</dc:creator><dc:creator>夏锅</dc:creator><dc:creator>Zhenjue Qian</dc:creator><dc:creator> Yuting Wen</dc:creator><dc:creator> Tangfeng LV</dc:creator><dc:creator> Xiuwei Zhang</dc:creator><dc:creator> Yong Song</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>线粒体SIRTUIN SIRT5在琥珀酸修饰和癌症发展中的新兴作用</dc:title><dc:identifier>PMID：39944690</dc:identifier><dc:identifier> PMC：PMC11814216</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1531246</dc:identifier></item><item><title>功能失调的β细胞自噬可诱导β细胞应力并增强胰岛免疫原性</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944686/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description>结论：我们的发现表明β细胞自噬对细胞存活/功能至关重要。有缺陷的β细胞自噬会诱导ER应力，改变抗原产生的途径，并增强MHC-I/HLA-I呈现以监测免疫细胞。总体而言，我们的结果表明，自噬的缺陷使β细胞更容易受到免疫攻击和破坏。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1504583。 doi：10.3389/fimmu.2025.1504583。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：1型糖尿病（T1D）是由遗传和环境因素的组合引起的，这些因素和环境因素触发自身免疫性介导的胰腺β细胞破坏。 β细胞应力反应途径（例如自噬）的缺陷可能在激活和/或加剧疾病发育中的免疫反应中起重要作用。以前，我们发现β细胞自噬在T1D发作之前受到损害，这意味着T1D发病机理中这一途径。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估自噬在β细胞健康和生存中的作用，以及自噬渲染胰岛缺陷是否更加免疫原性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们在小鼠的β细胞（ <sup>ATG7Δβ细胞</sup>）中淘汰了关键的自噬酶ATG7，然后监测了血糖，进行了葡萄糖耐受性测试，并评估了散装胰岛mRNA和蛋白质。我们还评估了<sup>ATG7Δβ细胞</sup>中CD45+免疫细胞的MHC-I表达和存在，并评估了自噬受损如何影响基础和IFNα刺激条件下的Endoc-βH1HLA-I表达。最后，我们与糖尿病性BDC2.5辅助T细胞一起将<sup>ATG7Δβ细胞</sup>细胞共培养，并评估了T细胞活化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们发现所有ATG7δβ<sup>细胞</sup>小鼠都在11-15周龄之间出现糖尿病。基因本体分析显示，炎症过程中涉及的途径，对ER应激的反应以及与ER相关的降解途径的途径显着上调。有趣的是，我们还观察到参与MHC-I表现的蛋白质的上调，表明有缺陷的β细胞自噬可能会改变免疫肽组或抗原库，并增强β细胞免疫可见度。为了支持这一假设，我们观察到<sup>ATG7Δβ细胞</sup>胰岛中MHC-I表达和CD45+免疫细胞的增加。我们还证明，当自噬降解被抑制时，HLA-I在胚胎β细胞中被上调。在基础和IFNα刺激条件下都观察到了这种效果。相反，溶酶体酸化/功能的刺激剂C381降低了HLA-I表达。最后，我们表明，在存在有缺陷自噬的胰岛细胞的情况下，BDC2.5 T细胞的激活增强。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的发现表明β细胞自噬对细胞存活/功能至关重要。有缺陷的β细胞自噬会诱导ER应力，改变抗原产生的途径，并增强MHC-I/HLA-I呈现以监测免疫细胞。总体而言，我们的结果表明，自噬的缺陷使β细胞更容易受到免疫攻击和破坏。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39944686/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944686</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814175/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814175</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1504583>10.3389/fimmu.2025.1504583</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39944686</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator>马修·奥斯丁</dc:creator><dc:creator>Charanya Muralidharan</dc:creator><dc:creator> Saptarshi Roy</dc:creator><dc:creator>贾斯汀·J·克劳德（Justin J Crowder）</dc:creator><dc:creator>乔恩·皮纳内利（Jon d Piganelli）</dc:creator><dc:creator> Amelia K Linnemann</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>功能失调的β细胞自噬可诱导β细胞应力并增强胰岛免疫原性</dc:title><dc:identifier>PMID：39944686</dc:identifier><dc:identifier> PMC：PMC11814175</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1504583</dc:identifier></item><item><title>解锁免疫肽组的秘密：MHC分子，NCRNA肽和囊泡免疫反应</title><link/>https://pubmed.ncbi.nlm.nih.gov/39944685/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description>免疫肽组是由主要组织相容性复合物（MHC）分子提出的各种肽，是免疫识别和反应的关键组成部分。这篇评论文章深入研究了MHC分子的肽表现机制，尤其强调了NCRNA衍生的肽和细胞外囊泡（EV）在塑造免疫肽组景观中的作用。我们探索对MHC分子与肽的相互作用的建立和新兴见解，包括... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月29日； 16：1540431。 doi：10.3389/fimmu.2025.1540431。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">免疫肽组是由主要组织相容性复合物（MHC）分子提出的各种肽，是免疫识别和反应的关键组成部分。这篇评论文章深入研究了MHC分子的肽表现机制，尤其强调了NCRNA衍生的肽和细胞外囊泡（EV）在塑造免疫肽组景观中的作用。我们探讨了对MHC分子与肽相互作用的建立和新见解，包括肽负荷，转运和细胞和遗传变异的影响的动力学。本文重点介绍了有关非编码RNA（NCRNA）衍生肽的新型研究，这些研究挑战了抗原加工和表现的常规观点以及电动汽车在运输这些肽中的作用，从而调节了偏远人体部位的免疫反应。这项新颖的研究不仅挑战了传统观点，而且为理解免疫反应的新途径开辟了新的途径。 Furthermore, we discuss the implications of these mechanisms in developing therapeutic strategies, particularly for cancer immunotherapy. By conducting a comprehensive analysis of current literature and advanced methodologies in immunopeptidomics, this review aims to deepen the understanding of the complex interplay between MHC peptide presentation and the immune system, offering new perspectives on potential diagnostic and therapeutic applications. Additionally, the interactions between ncRNA-derived peptides and EVs provide a mechanism for the enhanced surface presentation of these peptides and highlight a novel pathway for their systemic distribution, potentially altering immune surveillance and therapeutic landscapes.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39944685/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944685</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814183/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814183</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1540431>10.3389/fimmu.2025.1540431</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39944685</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Arpita Balakrishnan</dc:creator><dc:creator> Gabriela Winiarek</dc:creator><dc:creator> Olga Hołówka</dc:creator><dc:creator> Jakub Godlewski</dc:creator><dc:creator> Agnieszka Bronisz</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>Unlocking the secrets of the immunopeptidome: MHC molecules, ncRNA peptides, and vesicles in immune response</dc:title><dc:identifier> pmid:39944685</dc:identifier><dc:identifier> pmc:PMC11814183</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1540431</dc:identifier></item><item><title> SECTM1 acts as an immune-related biomarker of poor prognosis and promotes cancer progression by modulating M2 macrophage polarization in esophageal squamous cell carcinoma</title><link/> https://pubmed.ncbi.nlm.nih.gov/39944684/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description> Esophageal squamous cell carcinoma (ESCC) is the most prevalent primary malignant esophageal tumor in China and has a poor prognosis, but lacks effective diagnostic and prognostic biomarkers. Through single-sample gene set enrichment analysis (ssGSEA), we conducted immune genomic analysis based on 28 immune features using transcriptomic data from 155 ESCC cases. We established of two ESCC subtypes characterized by high and low immune profiles, and 352 differentially expressed immune genes were... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 29;16:1507227. doi: 10.3389/fimmu.2025.1507227.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Esophageal squamous cell carcinoma (ESCC) is the most prevalent primary malignant esophageal tumor in China and has a poor prognosis, but lacks effective diagnostic and prognostic biomarkers. Through single-sample gene set enrichment analysis (ssGSEA), we conducted immune genomic analysis based on 28 immune features using transcriptomic data from 155 ESCC cases. We established of two ESCC subtypes characterized by high and low immune profiles, and 352 differentially expressed immune genes were identified between the two subtypes. Performed with univariate and multivariate Cox regression, a novel prognostic prediction model was developed based on three immune-related genes (MAP3K8, SECTM1, IGLV7-43), which has been identified as a relatively accurate, independent, and specific prognostic risk model for ESCC patients in different ESCC cohorts. Furthermore, SECTM1 was upregulated in ESCC tissues and associated with adverse clinical outcomes. In cell experiments, overexpression of SECTM1 effectively promoted the proliferation, migration, and invasion of ESCC cells, while SECTM1 knockdown significantly inhibited these cellular processes. Furthermore, its overexpression promoted macrophage polarization towards the M2-like phenotype and promoted the migration of M2-like macrophage cells and CC Motif Chemokine Ligand 5 (CCL5) was the key mediator in the pro-cancer effect of SECTM1. In a Conclusion, our study established a prognostic prediction model based on immune-related gene signature, which provided a reliable prognostic tool for ESCC and identified SECTM1 as a potential biomarker in ESCC.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39944684/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944684</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814170/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814170</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1507227>10.3389/fimmu.2025.1507227</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39944684</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Pengzhou Kong</dc:creator><dc:creator> Ye Jiao</dc:creator><dc:creator> Meng Sun</dc:creator><dc:creator> Zhinan Zhou</dc:creator><dc:creator> Yingying Zhang</dc:creator><dc:creator> Xin Yang</dc:creator><dc:creator> Jing Ren</dc:creator><dc:creator> Mengyuan Yang</dc:creator><dc:creator> Yanyan Dong</dc:creator><dc:creator> Bin Song</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>SECTM1 acts as an immune-related biomarker of poor prognosis and promotes cancer progression by modulating M2 macrophage polarization in esophageal squamous cell carcinoma</dc:title><dc:identifier> pmid:39944684</dc:identifier><dc:identifier> pmc:PMC11814170</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1507227</dc:identifier></item><item><title> Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience</title><link/> https://pubmed.ncbi.nlm.nih.gov/39944683/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description> CONCLUSION: This study highlighted the evolving trends in DLI practices and the diversification of combination therapies. Future research should focus on further validating these findings and optimizing DLI protocols to improve patient outcomes. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 29;16:1521895. doi: 10.3389/fimmu.2025.1521895.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: Donor lymphocyte infusion (DLI) is a therapeutic approach for relapse after hematopoietic stem cell transplantation (HSCT). Despite their reported efficacy, the evolution of DLI practices over time remains underexplored. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This study provided a comprehensive analysis of DLI strategies and outcomes over 30 years at a single institution. A retrospective analysis was conducted on 75 patients who underwent DLI for disease relapse between April 1994 and March 2024. The primary endpoint was the 3-year overall survival (OS) rate after DLI. Secondary endpoints included the 100-day complete remission (CR) rate and incidence of acute graft-versus-host disease (GVHD). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The median age at the first DLI was 49 years (range, 20-69 years). The most common underlying diseases in all 75 cases were acute myeloid leukemia (AML, n = 46) and myelodysplastic syndromes (MDS, n = 12). Until 2014, DLI was only performed in patients with AML (n = 14), MDS (n = 2), or chronic myeloid leukemia (n = 5). However, since 2015, patients with various diseases, including lymphoid malignancies, have also undergone DLI. Azacitidine was the most frequently used combination therapy with DLI (n = 34). Regimens including venetoclax and FLT3 inhibitors have been commonly used since 2019 (n = 18). The 3-year OS rate was 29.1% (95% CI, 18.8-40.2%). Factors negatively influencing OS included age ≥50 years and a high or very high refined disease risk index. The 100-day CR rate was 52.1%, and acute GVHD occurred in 25.3% of the patients, with no strong correlation between GVHD incidence and CR achievement. Among 18 patients who underwent three or more DLIs since 2018, 88.9% achieved remission following DLI or second HSCT, with a median follow-up of 949.5 days for survivors. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: This study highlighted the evolving trends in DLI practices and the diversification of combination therapies. Future research should focus on further validating these findings and optimizing DLI protocols to improve patient outcomes.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39944683/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944683</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814185/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814185</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1521895>10.3389/fimmu.2025.1521895</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39944683</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Yusuke Uchibori</dc:creator><dc:creator> Shuhei Kurosawa</dc:creator><dc:creator> Yuho Najima</dc:creator><dc:creator> Kyoko Haraguchi</dc:creator><dc:creator> Daichi Sadato</dc:creator><dc:creator> Chizuko Hirama</dc:creator><dc:creator> Yasutaka Sadaga</dc:creator><dc:creator> Kaori Kondo</dc:creator><dc:creator> Chika Kato</dc:creator><dc:creator> Satoshi Sakai</dc:creator><dc:creator> Yasuhiro Kambara</dc:creator><dc:creator> Fumihiko Ouchi</dc:creator><dc:creator> Masashi Shimabukuro</dc:creator><dc:creator> Atsushi Jinguji</dc:creator><dc:creator> Naoki Shingai</dc:creator><dc:creator> Takashi Toya</dc:creator><dc:creator> Hiroaki Shimizu</dc:creator><dc:creator> Takeshi Kobayashi</dc:creator><dc:creator> Hironori Harada</dc:creator><dc:creator> Yuka Harada</dc:creator><dc:creator> Yoshiki Okuyama</dc:creator><dc:creator> Noriko Doki</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience</dc:title><dc:identifier> pmid:39944683</dc:identifier><dc:identifier> pmc:PMC11814185</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1521895</dc:identifier></item><item><title> Molecular assessment of splicing variants in a cohort of patients with inborn errors of immunity: methodological approach and interpretation remarks</title><link/> https://pubmed.ncbi.nlm.nih.gov/39944559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250213111310&amp;v=2.18.0.post9+e462414<description> CONCLUSION: This study shows the proportion of splicing variants in a cohort of IEI patients, providing their clinical phenotypic characteristics and the methodology used to validate the splicing defects. Based on the results, an algorithm is proposed to clarify when a splicing variant should be validated by complementary methodology and when, by contrast, it can be directly considered disease causing. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 29;15:1499415. doi: 10.3389/fimmu.2024.1499415.环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Splicing is the molecular mechanism to produce mature messenger RNA (mRNA) before its translation into protein. It is estimated that 50% of disease-causing mutations disrupt splicing, mostly of them affecting canonical positions. However, variants occurring in coding regions or deep-intronic variants can also affect splicing. In these cases, interpretation of the results may be challenging and molecular validation is required. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The study includes 23 patients with splicing variants out of a cohort of 187 patients diagnosed with inborn errors of immunity (IEI). Clinical features and immunophenotypes are shown. Reverse transcription-polymerase chain reaction (RT-PCR) is the molecular assay employed for pathogenicity validation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We detected 23 patients of 20 pedigrees with splicing variants in IEI genes, which constitutes the 12.3% of our cohort. In total, 21 splicing variants were analyzed, 10 of which had previously been reported in the literature and 11 novel ones. Among the 23 patients, 16 showed variants at canonical splice sites. Molecular validation was required only in the cases of genes of uncertain significance (GUS), high homology pseudogenes or incompatible clinical phenotype. Seven patients showed variants outside canonical positions. All of them needed molecular validation, with the exception of two patients, whose variants had previously been well characterized in the medical literature. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: This study shows the proportion of splicing variants in a cohort of IEI patients, providing their clinical phenotypic characteristics and the methodology used to validate the splicing defects. Based on the results, an algorithm is proposed to clarify when a splicing variant should be validated by complementary methodology and when, by contrast, it can be directly considered disease causing.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39944559/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">39944559</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11814461/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250213111310&v=2.18.0.post9+e462414">PMC11814461</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1499415>10.3389/fimmu.2024.1499415</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39944559</guid><pubDate> Thu, 13 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Laura Miguel Berenguel</dc:creator><dc:creator> Carla Gianelli</dc:creator><dc:creator> Elisabet Matas Pérez</dc:creator><dc:creator> Teresa Del Rosal</dc:creator><dc:creator> Ana Méndez Echevarría</dc:creator><dc:creator> Ángel Robles Marhuenda</dc:creator><dc:creator> Marta Feito Rodríguez</dc:creator><dc:creator> Maria Teresa Caballero Molina</dc:creator><dc:creator> Lorena Magallares García</dc:creator><dc:creator> Brenda Sánchez Garrido</dc:creator><dc:creator> Samantha Hita Díaz</dc:creator><dc:creator> Luis Allende Martínez</dc:creator><dc:creator> Pilar Nozal Aranda</dc:creator><dc:creator> Carmen Cámara Hijón</dc:creator><dc:creator> Eduardo López Granados</dc:creator><dc:creator> Rebeca Rodríguez Pena</dc:creator><dc:creator> María Bravo García-Morato</dc:creator><dc:date> 2025-02-13</dc:date><dc:source>免疫学领域</dc:source><dc:title>Molecular assessment of splicing variants in a cohort of patients with inborn errors of immunity: methodological approach and interpretation remarks</dc:title><dc:identifier> pmid:39944559</dc:identifier><dc:identifier> pmc:PMC11814461</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1499415</dc:identifier></item></channel></rss>